AstraZeneca’s earnings surprise investors as cancer drugs fuel growth
IMFINZI® (durvalumab) plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial
said on Friday its blockbuster cancer drug Imfinzi helped improve survival in patients in the early stages of an aggressive type of lung cancer, making it the first such immunotherapy to meet two key trial goals.
IMFINZI® (durvalumab) significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trial
AstraZeneca Shows Lynparza Combo Could Address Unmet Endometrial Cancer Need
OCALA, Fla., Feb. 14, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (œAIM or the œCompany) today announced the first subject has been dosed at Erasmus Medical Center (œErasmus...
OCALA, Fla., Jan. 22, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (AIM or the Company) today announced that the first subject has been enrolled at Erasmus Medical Center...
Imfinzi combo extends progression-free survival in liver cancer: In a Phase III trial, AstraZeneca’s Imfinzi plus bevacizumab, otherwise known as Avastin, on top of a standard care chemotherapy treatment called TACE for liver cancer, staved off cancer progression longer than the chemotherapy treatment alone. The EMERALD-1 study included over 600 patients with hepatocellular carcinoma, which is the most common form of liver cancer and can’t be removed by surgery. However, these patients were eligible for embolization, the procedure used for TACE.
First enrollment and first subject dosing expected soon at Erasmus Medical Center in Rotterdam, Netherlands Management discusses the announcement and what this means here: video OCALA, Fla.,...